tiprankstipranks
Ocular Therapeutix Inc (CH:0OT)
NASDAQ:0OT

Ocular Therapeutix (0OT) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Ocular Therapeutix has a market cap or net worth of CHF1.69B. The enterprise value is $1.52B.
Market CapCHF1.69B
Enterprise Value$1.52B

Share Statistics

Ocular Therapeutix has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding
Owned by Insiders2.72%
Owned by Institutions40.35%

Financial Efficiency

Ocular Therapeutix’s return on equity (ROE) is -0.41 and return on invested capital (ROIC) is -35.53%.
Return on Equity (ROE)-0.41
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-35.53%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee189.14K
Profits Per Employee-970.58K
Employee Count274
Asset Turnover0.06
Inventory Turnover1.84

Valuation Ratios

The current PE Ratio of Ocular Therapeutix is ―. Ocular Therapeutix’s PEG ratio is -0.52.
PE Ratio
PS Ratio43.86
PB Ratio3.47
Price to Fair Value3.47
Price to FCF-10.48
Price to Operating Cash Flow-9.55
PEG Ratio-0.52

Income Statement

In the last 12 months, Ocular Therapeutix had revenue of 51.82M and earned -265.94M in profits. Earnings per share was -1.42.
Revenue51.82M
Gross Profit45.25M
Operating Income-270.02M
Pretax Income-265.94M
Net Income-265.94M
EBITDA-249.78M
Earnings Per Share (EPS)-1.42

Cash Flow

In the last 12 months, operating cash flow was -226.21M and capital expenditures -14.74M, giving a free cash flow of -240.94M billion.
Operating Cash Flow-226.21M
Free Cash Flow-240.94M
Free Cash Flow per Share-10.00T>

Dividends & Yields

Ocular Therapeutix pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta8.76
52-Week Price Change
50-Day Moving Average
200-Day Moving Average
Relative Strength Index (RSI)
Average Volume (3m)

Important Dates

Ocular Therapeutix upcoming earnings date is Aug 10, 2026, After Close (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date

Financial Position

Ocular Therapeutix as a current ratio of 15.39, with Debt / Equity ratio of 13.66%
Current Ratio15.39
Quick Ratio15.32
Debt to Market Cap0.03
Net Debt to EBITDA2.63
Interest Coverage Ratio-22.82

Taxes

In the past 12 months, Ocular Therapeutix has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Ocular Therapeutix EV to EBITDA ratio is -6.47, with an EV/FCF ratio of -7.45.
EV to Sales31.18
EV to EBITDA-6.47
EV to Free Cash Flow-7.45
EV to Operating Cash Flow-7.89

Balance Sheet

Ocular Therapeutix has CHF666.70M in cash and marketable securities with CHF79.46M in debt, giving a net cash position of CHF587.24M billion.
Cash & Marketable SecuritiesCHF666.70M
Total DebtCHF79.46M
Net CashCHF587.24M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF3.49

Margins

Gross margin is 87.24%, with operating margin of -521.04%, and net profit margin of -513.17%.
Gross Margin87.24%
Operating Margin-521.04%
Pretax Margin-513.17%
Net Profit Margin-513.17%
EBITDA Margin-481.99%
EBIT Margin-490.33%

Analyst Forecast

The average price target for Ocular Therapeutix is CHF20.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetCHF20.63
Price Target Upside― Downside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart Score4
AI Score